2,4-Dimethyl-5-ethoxy-oxazol | 5214-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,4-Dimethyl-5-ethoxy-oxazol
• 英文别名: 2,4-dimethyl 5-ethoxyoxazole；5-ethoxy-2,4-dimethyloxazole；5-Ethoxy-2,4-dimethyl-1,3-oxazole
• CAS: 5214-62-0
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: JORFSVIFVBADEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2,4-Dimethyl-5-ethoxy-oxazol 在 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Evaluation of 1,2-dimethyl-3-hydroxy-4-pyridinecarboxylic acid and of other 3-hydroxy-4-pyridinecarboxylic acid derivatives for possible application in iron and aluminium chelation therapy

  摘要：

  Four new possible chelating agents for iron and aluminium, 1,2-dimethyl-3-hydroxy-4-pyridinecarboxylic acid (DT712), 3-hydroxy-1,2,6-trimethyl-4-pyridinecarboxylic acid, 2,6-dimethyl-3-hydroxy-4-pyridinecarboxylic acid, and 2-ethyl-3-hydroxy-1-methyl-4-pyridinecarboxylic acid, were synthesized, and their complex formation with Fe(III) and Al(III) was studied by potentiometry, UV-Vis, H-1 NMR, and electrospray mass spectrometry (ESI-MS). Number, stoichiometry, and stability constants of metal-ligand complexes were obtained at 25 C in aqueous (Na)Cl 0.6 m. DT712 is the most promising hydroxypyridinecarboxylic acid considered so far for iron chelation therapy, as it forms the strongest Fe(III) complexes. This compound was further investigated to better clarify its possible behaviour in vivo with particular respect to iron chelation therapy. UV-Vis measurements were performed to determine the kinetics by which DT712 extracts Fe(III) from transferrin. DT712 resulted to have better kinetic properties than existing iron chelators. Ternary metal/DT712/citric acid complexes were studied by ESI-MS to check the competition with a typical low molecular weight ligand in the blood. The formation of only binary Fe(III)/ DT712 and Al(III)/DT712 complexes (and ternary complexes in aged solutions), suggests that DT712 effectively compete with citric acid in the metal complexation. Standard reduction potentials of Fe(III)/DT712 complexes, and the kinetic constants of complex formation, were obtained by cyclic voltammetiy. Accordingly, no redox cycling is expected to occur at in vivo conditions, and Fe(III)/DT712 complex formation should not be kinetically limited. On the basis of the present results, DT712 is proposed as candidate for iron chelation therapy. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2013.10.007
• 作为产物：
  描述：

  乳酸乙酯 在 2,6-二甲基吡啶 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 反应 1.55h， 生成 2,4-Dimethyl-5-ethoxy-oxazol
  参考文献：
  名称：

  从α-三氟乙氧基酯和腈中快速微波辅助合成5-烷氧基恶唑

  摘要：

  据报道，从易于获得的α-三氟乙氧基/羟基酯1和腈中，可以快速，普遍地获得各种取代的5-烷氧基恶唑2（即R 1，R 2 =烷基，苯基），产率高（41-76％）。示出了环化的多功能性，其对于一系列对甲磺酸酯上的三氟甲磺酸酯具有高选择性的底物，并证明与敏感的官能团相容。为了说明这种转变，最近分离出的羟基吡啶甲基多juguinate 4的第一个合成过程是通过5-烷氧基恶唑和丙烯酸的杂Diels-Alder反应，然后进行原脱羧反应，分四个步骤完成的。

  DOI：

  10.1021/jo301527t

文献信息

• N-substituted benzothiophenesulfonamide derivatives
  申请人：TOA EIYO Ltd.

  公开号：US20030229126A1

  公开（公告）日：2003-12-11

  The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

  本发明涉及一种N-取代苯并噻吩磺酰胺衍生物或其药用可接受盐及其应用。此外，它提供了一种用于预防或治疗由于针对钙蛋白酶活性引起的血管紧张素II或内皮素I的异常增加，或由于肥大细胞的活化引起的心脏或循环疾病等的药剂，以及一种用于手术后预防粘连的药剂，其中该药剂对钙蛋白酶具有选择性抑制作用。
• [EN] NEPRILYSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116786A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式（I）的化合物：其中R1-R6定义如说明书中所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Visible-Light-Mediated Synthesis of Oxidized Amides via Organic Photoredox Catalysis
  作者：Ting Wang、Yuliu Du、Zheng Wei

  DOI：10.1055/s-0036-1591988

  日期：2018.9

  Applications in Synthesis Abstract The development of visible-light-mediated synthesis of oxidized amides is reported. The reaction shows a broad substrate scope and highlights a mild nature of the reaction conditions. A range of functional groups are well tolerated in the reaction. Relying on the strategy, a variety of α-alkoxy amino acids are synthesized. The development of visible-light-mediated synthesis

  作为特别主题的光氧化还原方法及其在合成中的战略应用的一部分发布 抽象的 报道了可见光介导的氧化酰胺合成的发展。该反应显示出较宽的底物范围并突出了反应条件的温和性质。反应中对一系列官能团的耐受性良好。依靠该策略，合成了多种α-烷氧基氨基酸。 报道了可见光介导的氧化酰胺合成的发展。该反应显示出较宽的底物范围并突出了反应条件的温和性质。反应中对一系列官能团的耐受性良好。依靠该策略，合成了多种α-烷氧基氨基酸。
• Total synthesis of (±)-paniculide-a
  作者：Peter A. Jacobi、Colleen S.R. Kaczmarek、Uko E. Udodong

  DOI：10.1016/s0040-4020(01)87731-0

  日期：1987.1

  paniculide A precursor 4 has been achieved beginning with 3-methylglutaric anhydride, and utilizing as the key step an intramolecular Diels-Alder reaction of an acetylenic oxazole to give a 2-methoxyfuran. Acid hydrolysis then provided the requisite butenolide ring characteristic of the paniculides.

  从3-甲基戊二酸酐开始，并以炔属恶唑的分子内Diels-Alder反应为关键步骤，以得到2-甲氧基呋喃，从而实现了抗草酸酯A前体4的有效合成。然后，酸水解提供了必需的抗坏血酸丁酸酯环。
• [EN] 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE 5-BIPHÉNYL-4-HÉTÉOARYLCARBONYLAMINO-PENTANOÏQUE UTILISÉS EN TANT QU'INHIBITEURS DE NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116760A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式（I）的化合物：其中R1、R2a、R2b和R3-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包括这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。